Matches in SemOpenAlex for { <https://semopenalex.org/work/W1626821504> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W1626821504 endingPage "5501" @default.
- W1626821504 startingPage "5501" @default.
- W1626821504 abstract "Introduction: ABT-737 is a small molecule inhibitor of Bcl-2, Bcl-xL and Bcl-w which has been shown to induce apoptosis in a variety of tumor types. Persistence of Mcl-1 expression has been proposed as a potential mechanism of resistance to ABT-737. Sorafenib is a multitargeted tyrosine kinase inhibitor of VEGFR2, PDGFR, B-raf, and C-raf and has been shown to downmodulate Mcl-1. We have previously shown that sorafenib can induce caspase-dependent apoptosis in A375 cells and caspase-independent apoptosis in A2058 cells through enhancement of the nuclear translocation of apoptosis inducible factor (AIF). We sought to evaluate the efficacy of ABT-737 in melanoma and determine if its effects may be additive to those of sorafenib. Experimental Methods: Varying doses of ABT-737 (0-10 µM) and sorafenib (5-20 µM) were used to treat A375 and A2058 melanoma cells which were analyzed for viability by propidium iodide staining as well as lysed for western blot analysis for Mcl-1, total and phosphorylated Erk, and PARP. Dependence of observed cytotoxicity on caspase activation was determined by concurrent treatment with the pan-caspase inhibitor Z-VAD. Results: Treatment with ABT-737 resulted in only modest single-agent lethality in both A375 and A2058 cell lines. However, concurrent treatment with sorafenib resulted in synergistic enhancement of lethality compared with either agent alone. This synergy was observed at sorafenib concentrations sufficient to downmodulate Mcl-1 but insufficient to inhibit Erk phosphorylation. Concurrent treatment with Z-VAD reverses the effects of the combination in the A375 cell line but not in the A2058 cell line, suggesting that ABT-737 may enhance the previously described effects of sorafenib on the nuclear translocation of AIF in this cell line. Conclusions: The combination of ABT-737 and sorafenib leads to synergistic cytotoxicity in melanoma cell lines. This effect appears independent of the inhibition of raf by sorafenib and is correlated instead with the downmodulation of Mcl-1. The variable dependence of this synergy on caspase activation suggests that the mechanism of lethality may differ between cell lines. Cellular fractionation assays are ongoing to explore the effects of the combination on nuclear translocation of AIF. Given the paucity of effective therapies in malignant melanoma, the combination of inhibitors of Bcl-2 family members with sorafenib may be an attractive combination to advance to clinical assessment. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5501." @default.
- W1626821504 created "2016-06-24" @default.
- W1626821504 creator A5008479799 @default.
- W1626821504 creator A5029055683 @default.
- W1626821504 creator A5052526230 @default.
- W1626821504 creator A5061578231 @default.
- W1626821504 creator A5066250381 @default.
- W1626821504 creator A5080231807 @default.
- W1626821504 date "2009-05-01" @default.
- W1626821504 modified "2023-09-24" @default.
- W1626821504 title "Abstract #5501: In vitro synergy of the combination of Sorafenib and ABT-737 in melanoma cell lines" @default.
- W1626821504 hasPublicationYear "2009" @default.
- W1626821504 type Work @default.
- W1626821504 sameAs 1626821504 @default.
- W1626821504 citedByCount "1" @default.
- W1626821504 countsByYear W16268215042015 @default.
- W1626821504 crossrefType "journal-article" @default.
- W1626821504 hasAuthorship W1626821504A5008479799 @default.
- W1626821504 hasAuthorship W1626821504A5029055683 @default.
- W1626821504 hasAuthorship W1626821504A5052526230 @default.
- W1626821504 hasAuthorship W1626821504A5061578231 @default.
- W1626821504 hasAuthorship W1626821504A5066250381 @default.
- W1626821504 hasAuthorship W1626821504A5080231807 @default.
- W1626821504 hasConcept C121608353 @default.
- W1626821504 hasConcept C126322002 @default.
- W1626821504 hasConcept C184235292 @default.
- W1626821504 hasConcept C185592680 @default.
- W1626821504 hasConcept C190283241 @default.
- W1626821504 hasConcept C2775934118 @default.
- W1626821504 hasConcept C2777658100 @default.
- W1626821504 hasConcept C2778019345 @default.
- W1626821504 hasConcept C2778695046 @default.
- W1626821504 hasConcept C2778820342 @default.
- W1626821504 hasConcept C31573885 @default.
- W1626821504 hasConcept C502942594 @default.
- W1626821504 hasConcept C53227056 @default.
- W1626821504 hasConcept C55493867 @default.
- W1626821504 hasConcept C57074206 @default.
- W1626821504 hasConcept C71924100 @default.
- W1626821504 hasConcept C98274493 @default.
- W1626821504 hasConceptScore W1626821504C121608353 @default.
- W1626821504 hasConceptScore W1626821504C126322002 @default.
- W1626821504 hasConceptScore W1626821504C184235292 @default.
- W1626821504 hasConceptScore W1626821504C185592680 @default.
- W1626821504 hasConceptScore W1626821504C190283241 @default.
- W1626821504 hasConceptScore W1626821504C2775934118 @default.
- W1626821504 hasConceptScore W1626821504C2777658100 @default.
- W1626821504 hasConceptScore W1626821504C2778019345 @default.
- W1626821504 hasConceptScore W1626821504C2778695046 @default.
- W1626821504 hasConceptScore W1626821504C2778820342 @default.
- W1626821504 hasConceptScore W1626821504C31573885 @default.
- W1626821504 hasConceptScore W1626821504C502942594 @default.
- W1626821504 hasConceptScore W1626821504C53227056 @default.
- W1626821504 hasConceptScore W1626821504C55493867 @default.
- W1626821504 hasConceptScore W1626821504C57074206 @default.
- W1626821504 hasConceptScore W1626821504C71924100 @default.
- W1626821504 hasConceptScore W1626821504C98274493 @default.
- W1626821504 hasLocation W16268215041 @default.
- W1626821504 hasOpenAccess W1626821504 @default.
- W1626821504 hasPrimaryLocation W16268215041 @default.
- W1626821504 hasRelatedWork W2004186722 @default.
- W1626821504 hasRelatedWork W2055695980 @default.
- W1626821504 hasRelatedWork W2066404900 @default.
- W1626821504 hasRelatedWork W2071548786 @default.
- W1626821504 hasRelatedWork W2088371348 @default.
- W1626821504 hasRelatedWork W2209297786 @default.
- W1626821504 hasRelatedWork W2257157366 @default.
- W1626821504 hasRelatedWork W2269888391 @default.
- W1626821504 hasRelatedWork W2319328441 @default.
- W1626821504 hasRelatedWork W2331761697 @default.
- W1626821504 hasRelatedWork W2337923700 @default.
- W1626821504 hasRelatedWork W2340300548 @default.
- W1626821504 hasRelatedWork W2559785814 @default.
- W1626821504 hasRelatedWork W2579042246 @default.
- W1626821504 hasRelatedWork W2767056524 @default.
- W1626821504 hasRelatedWork W2895654604 @default.
- W1626821504 hasRelatedWork W2925963101 @default.
- W1626821504 hasRelatedWork W2967362211 @default.
- W1626821504 hasRelatedWork W2979572678 @default.
- W1626821504 hasRelatedWork W2979820519 @default.
- W1626821504 hasVolume "69" @default.
- W1626821504 isParatext "false" @default.
- W1626821504 isRetracted "false" @default.
- W1626821504 magId "1626821504" @default.
- W1626821504 workType "article" @default.